Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents, but more precise estimates of their effects on major adverse cardiovascular events (MACE), mortality, and safety are needed. We systematically reviewed and meta-analyzed randomized controlled tria...
Saved in:
Published in | Canadian journal of cardiology Vol. 34; no. 12; pp. 1600 - 1605 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Inc
01.12.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents, but more precise estimates of their effects on major adverse cardiovascular events (MACE), mortality, and safety are needed. We systematically reviewed and meta-analyzed randomized controlled trials with durations ≥ 6 months comparing MACE, mortality, and safety with PCSK9 inhibitors vs control. We searched CENTRAL, Embase, MedLine and the grey literature to November 7, 2018. From 2048 articles, we included 23 trials (n = 60,723). PCSK9 inhibitors reduced MACE (relative risk, 0.83; 95% confidence interval, 0.78-0.88), but did not clearly reduce mortality (relative risk, 0.93; 95% confidence interval, 0.85-1.02) or increase adverse events. In conclusion, PCSK9 inhibitors reduce nonfatal MACE, are well tolerated, but effects on mortality remain unclear.
Les inhibiteurs de la proprotéine convertase subtilisine/kexine de type 9 (PCSK9) sont des agents hypolipidémiants efficaces, mais il est nécessaire d’estimer de façon plus précise leur innocuité ainsi que leurs effets sur les événements indésirables cardiovasculaires majeurs (EICM) et la mortalité. Nous avons effectué une recension systématique et une méta-analyse des essais randomisés contrôlés d’une durée supérieure à 6 mois pour comparer les EICM, la mortalité et l’innocuité des inhibiteurs de la PCSK9 comparativement à des témoins. Nos recherches ont porté sur les publications dans les bases de données CENTRAL, Embase et MedLine et la littérature grise jusqu’au 7 novembre 2018. À partir de 2048 articles recensés, nous avons analysé 23 essais (n = 60 723). Les inhibiteurs de la PCSK9 ont réduit les EICM (risque relatif, 0,83; intervalle de confiance à 95 % : de 0,78 à 0,88), mais n’ont pas réduit la mortalité de façon nette (risque relatif, 0,93; intervalle de confiance à 95 % : de 0,85 à 1,02) ou entraîné une augmentation des événements indésirables. En conclusion, les inhibiteurs de la PCSK9 réduisent la fréquence des EICM non mortels et sont bien tolérés, mais leurs effets sur la mortalité restent à déterminer. |
---|---|
AbstractList | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents, but more precise estimates of their effects on major adverse cardiovascular events (MACE), mortality, and safety are needed. We systematically reviewed and meta-analyzed randomized controlled trials with durations ≥ 6 months comparing MACE, mortality, and safety with PCSK9 inhibitors vs control. We searched CENTRAL, Embase, MedLine and the grey literature to November 7, 2018. From 2048 articles, we included 23 trials (n = 60,723). PCSK9 inhibitors reduced MACE (relative risk, 0.83; 95% confidence interval, 0.78-0.88), but did not clearly reduce mortality (relative risk, 0.93; 95% confidence interval, 0.85-1.02) or increase adverse events. In conclusion, PCSK9 inhibitors reduce nonfatal MACE, are well tolerated, but effects on mortality remain unclear.
Les inhibiteurs de la proprotéine convertase subtilisine/kexine de type 9 (PCSK9) sont des agents hypolipidémiants efficaces, mais il est nécessaire d’estimer de façon plus précise leur innocuité ainsi que leurs effets sur les événements indésirables cardiovasculaires majeurs (EICM) et la mortalité. Nous avons effectué une recension systématique et une méta-analyse des essais randomisés contrôlés d’une durée supérieure à 6 mois pour comparer les EICM, la mortalité et l’innocuité des inhibiteurs de la PCSK9 comparativement à des témoins. Nos recherches ont porté sur les publications dans les bases de données CENTRAL, Embase et MedLine et la littérature grise jusqu’au 7 novembre 2018. À partir de 2048 articles recensés, nous avons analysé 23 essais (n = 60 723). Les inhibiteurs de la PCSK9 ont réduit les EICM (risque relatif, 0,83; intervalle de confiance à 95 % : de 0,78 à 0,88), mais n’ont pas réduit la mortalité de façon nette (risque relatif, 0,93; intervalle de confiance à 95 % : de 0,85 à 1,02) ou entraîné une augmentation des événements indésirables. En conclusion, les inhibiteurs de la PCSK9 réduisent la fréquence des EICM non mortels et sont bien tolérés, mais leurs effets sur la mortalité restent à déterminer. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents, but more precise estimates of their effects on major adverse cardiovascular events (MACE), mortality, and safety are needed. We systematically reviewed and meta-analyzed randomized controlled trials with durations ≥ 6 months comparing MACE, mortality, and safety with PCSK9 inhibitors vs control. We searched CENTRAL, Embase, MedLine and the grey literature to November 7, 2018. From 2048 articles, we included 23 trials (n = 60,723). PCSK9 inhibitors reduced MACE (relative risk, 0.83; 95% confidence interval, 0.78-0.88), but did not clearly reduce mortality (relative risk, 0.93; 95% confidence interval, 0.85-1.02) or increase adverse events. In conclusion, PCSK9 inhibitors reduce nonfatal MACE, are well tolerated, but effects on mortality remain unclear. |
Author | Pearson, Glen J. Tsuyuki, Ross T. Turgeon, Ricky D. Gyenes, Gabor T. |
Author_xml | – sequence: 1 givenname: Ricky D. surname: Turgeon fullname: Turgeon, Ricky D. – sequence: 2 givenname: Ross T. surname: Tsuyuki fullname: Tsuyuki, Ross T. – sequence: 3 givenname: Gabor T. orcidid: 0000-0002-1177-3784 surname: Gyenes fullname: Gyenes, Gabor T. – sequence: 4 givenname: Glen J. orcidid: 0000-0003-3281-7915 surname: Pearson fullname: Pearson, Glen J. email: Glen.Pearson@ualberta.ca |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30527147$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kEFv1DAQRi1URLeFP8AB-cglYewkdoK4oLBARatFZCvRk-XYY-pVNmntpCg3fjpZtnDkNJf3PWneGTnphx4JeckgZcDEm11qdkanHFiZQp4C8CdkxSomEgmyOCErKHmZ8JJ_PyVnMe4AcialeEZOMyi4ZLlckV-1DtYPDzqaqdOBrp3zRpuZ6t7SRjscZzo4-rVuvlT0or_1rR-HEN_SZo4j7vXoDf2GDx5__llc4agT3etujj4uvOkm6_sfdLxFuvlw0zTrG7q53tabq3VDt8Hr7jl56nQX8cXjPSfXH9fb-nNyufl0Ub-_TExWiDGxXAoubJsJ0C2IMstKrp1soawqh8wYl3EBBl0ubAVMl85VopWszStwheHZOXl99N6F4X7COKq9jwa7Tvc4TFFxVhQsX-KVC8qPqAlDjAGdugt-r8OsGKhDebVTh_LqUF5Brpbyy-jVo39q92j_Tf6mXoB3RwCXL5dgQUXjsTdofUAzKjv4__l_A6HPlbo |
CitedBy_id | crossref_primary_10_15829_1560_4071_2021_4449 crossref_primary_10_1155_2019_8563845 crossref_primary_10_1016_j_revmed_2020_11_007 crossref_primary_10_2147_VHRM_S261719 crossref_primary_10_1177_17151635211006166 crossref_primary_10_1016_j_ijcrp_2022_200145 crossref_primary_10_1177_10742484221100107 crossref_primary_10_1016_j_cjca_2021_03_016 crossref_primary_10_1097_01_NPR_0000000000000059 crossref_primary_10_1097_CM9_0000000000002057 crossref_primary_10_23736_S0392_9590_21_04632_0 crossref_primary_10_1038_s41392_022_01125_5 crossref_primary_10_1097_MD_0000000000038360 crossref_primary_10_3389_fcvm_2023_1206156 crossref_primary_10_20996_1819_6446_2021_12_01 crossref_primary_10_1016_j_metabol_2022_155265 crossref_primary_10_1097_MOL_0000000000000631 crossref_primary_10_1016_j_pharmthera_2020_107592 crossref_primary_10_1016_j_cjca_2023_08_003 crossref_primary_10_1093_eurheartj_suaa063 crossref_primary_10_1007_s12325_020_01259_4 crossref_primary_10_1080_17512433_2020_1787832 crossref_primary_10_1136_bmjopen_2021_057856 crossref_primary_10_1002_14651858_CD011748_pub3 crossref_primary_10_3390_ijerph192416899 crossref_primary_10_1016_j_atherosclerosis_2019_07_015 crossref_primary_10_1016_j_atherosclerosis_2021_06_913 |
Cites_doi | 10.1016/S2213-8587(16)30396-5 10.1136/bmj.d5928 10.1056/NEJMoa1604304 10.1016/j.cjca.2016.07.510 10.1016/j.jclinepi.2010.07.015 10.1056/NEJMoa1615664 10.1016/j.jacc.2017.10.001 10.1016/j.cjca.2016.12.007 10.1371/journal.pmed.1000100 10.1056/NEJMoa1801174 10.1161/JAHA.117.006910 10.1161/CIRCULATIONAHA.115.016080 10.1016/j.cjca.2016.10.019 |
ContentType | Journal Article |
Copyright | 2018 Canadian Cardiovascular Society Copyright © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2018 Canadian Cardiovascular Society – notice: Copyright © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.cjca.2018.04.002 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1916-7075 |
EndPage | 1605 |
ExternalDocumentID | 10_1016_j_cjca_2018_04_002 30527147 S0828282X18302538 |
Genre | Meta-Analysis Systematic Review Journal Article |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1P~ 1~. 1~5 29B 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAXUO ABBQC ABFNM ABJNI ABLJU ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFO ACJTP ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXBA AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AISVY AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV E3Z EBS EFJIC EFLBG EJD F5P FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HX~ HYE HZ~ J1W KOM LCYCR M41 MO0 NAHTW O-L O9- OAUVE OA~ OK1 OL0 P-8 P-9 P2P PC. Q38 ROL RPM SDF SEL SES SJN SNG SPCBC SSH SSZ T5K TR2 Z5R ~G- AAXKI ADVLN AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c356t-d27626db360ab0683382af7b0899fe1ccf3260cef46d901a8ff96b71b490f5c23 |
IEDL.DBID | AIKHN |
ISSN | 0828-282X |
IngestDate | Fri Aug 16 01:46:33 EDT 2024 Thu Sep 26 17:57:42 EDT 2024 Wed Oct 16 00:51:26 EDT 2024 Fri Feb 23 02:12:54 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Language | English |
License | Copyright © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c356t-d27626db360ab0683382af7b0899fe1ccf3260cef46d901a8ff96b71b490f5c23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-1177-3784 0000-0003-3281-7915 |
PMID | 30527147 |
PQID | 2155149168 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_2155149168 crossref_primary_10_1016_j_cjca_2018_04_002 pubmed_primary_30527147 elsevier_sciencedirect_doi_10_1016_j_cjca_2018_04_002 |
PublicationCentury | 2000 |
PublicationDate | December 2018 2018-12-00 20181201 |
PublicationDateYYYYMMDD | 2018-12-01 |
PublicationDate_xml | – month: 12 year: 2018 text: December 2018 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Canadian journal of cardiology |
PublicationTitleAlternate | Can J Cardiol |
PublicationYear | 2018 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Bergeron, Phan, Ding, Fong, Krauss (bib4) 2015; 132 Waters, Boekholdt (bib2) 2017; 33 Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome [Epub ahead of print]. N Engl J Med Balshem, Helfand, Schünemann (bib9) 2011; 64 Ference, Robinson, Brook (bib13) 2016; 375 Anderson, Grégoire, Pearson (bib1) 2016; 32 Sabatine, Giugliano, Keech (bib5) 2017; 376 Liberati, Altman, Tetzlaff (bib7) 2009; 6 Schmidt, Swerdlow, Holmes (bib14) 2017; 5 Higgins, Altman, Gøtzsche (bib8) 2011; 343 Anderson (bib3) 2017; 33 Hlatky, Kazi (bib12) 2017; 70 Schmidt, Pearce, Wilkins (bib10) 2017 Karatasakis, Danek, Karacsonyi (bib11) 2017; 6 accessed November 9, 2018. Balshem (10.1016/j.cjca.2018.04.002_bib9) 2011; 64 Schmidt (10.1016/j.cjca.2018.04.002_bib14) 2017; 5 Anderson (10.1016/j.cjca.2018.04.002_bib3) 2017; 33 Higgins (10.1016/j.cjca.2018.04.002_bib8) 2011; 343 Schmidt (10.1016/j.cjca.2018.04.002_bib10) 2017 Bergeron (10.1016/j.cjca.2018.04.002_bib4) 2015; 132 Waters (10.1016/j.cjca.2018.04.002_bib2) 2017; 33 10.1016/j.cjca.2018.04.002_bib6 Anderson (10.1016/j.cjca.2018.04.002_bib1) 2016; 32 Ference (10.1016/j.cjca.2018.04.002_bib13) 2016; 375 Liberati (10.1016/j.cjca.2018.04.002_bib7) 2009; 6 Sabatine (10.1016/j.cjca.2018.04.002_bib5) 2017; 376 Hlatky (10.1016/j.cjca.2018.04.002_bib12) 2017; 70 Karatasakis (10.1016/j.cjca.2018.04.002_bib11) 2017; 6 |
References_xml | – volume: 132 start-page: 1648 year: 2015 end-page: 1666 ident: bib4 article-title: Proprotein convertase subtilisin/kexin type 9 inhibition a new therapeutic mechanism for reducing cardiovascular disease risk publication-title: Circulation contributor: fullname: Krauss – volume: 6 start-page: e1000100 year: 2009 ident: bib7 article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration publication-title: PLoS Med contributor: fullname: Tetzlaff – volume: 5 start-page: 97 year: 2017 end-page: 105 ident: bib14 article-title: PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study publication-title: Lancet Diabetes Endocrinol contributor: fullname: Holmes – volume: 376 start-page: 1713 year: 2017 end-page: 1722 ident: bib5 article-title: Evolocumab and clinical outcomes in patients with cardiovascular disease publication-title: N Engl J Med contributor: fullname: Keech – volume: 32 start-page: 1263 year: 2016 end-page: 1282 ident: bib1 article-title: 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult publication-title: Can J Cardiol contributor: fullname: Pearson – volume: 33 start-page: 405 year: 2017 end-page: 408 ident: bib3 article-title: Optimal low-density lipoprotein cholesterol for cardiovascular prevention: how low should we go? publication-title: Can J Cardiol contributor: fullname: Anderson – volume: 6 start-page: e006910 year: 2017 ident: bib11 article-title: Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials publication-title: J Am Heart Assoc contributor: fullname: Karacsonyi – start-page: CD011748 year: 2017 ident: bib10 article-title: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease publication-title: Cochrane Database Syst Rev contributor: fullname: Wilkins – volume: 343 start-page: d5928 year: 2011 ident: bib8 article-title: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials publication-title: BMJ contributor: fullname: Gøtzsche – volume: 33 start-page: 343 year: 2017 end-page: 349 ident: bib2 article-title: An evidence-based guide to cholesterol-lowering guidelines publication-title: Can J Cardiol contributor: fullname: Boekholdt – volume: 64 start-page: 401 year: 2011 end-page: 406 ident: bib9 article-title: GRADE guidelines: 3. Rating the quality of evidence publication-title: J Clin Epidemiol contributor: fullname: Schünemann – volume: 375 start-page: 2144 year: 2016 end-page: 2153 ident: bib13 article-title: Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes publication-title: N Engl J Med contributor: fullname: Brook – volume: 70 start-page: 2677 year: 2017 end-page: 2687 ident: bib12 article-title: PCSK9 inhibitors: economics and policy publication-title: J Am Coll Cardiol contributor: fullname: Kazi – volume: 5 start-page: 97 year: 2017 ident: 10.1016/j.cjca.2018.04.002_bib14 article-title: PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(16)30396-5 contributor: fullname: Schmidt – volume: 343 start-page: d5928 year: 2011 ident: 10.1016/j.cjca.2018.04.002_bib8 article-title: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials publication-title: BMJ doi: 10.1136/bmj.d5928 contributor: fullname: Higgins – volume: 375 start-page: 2144 year: 2016 ident: 10.1016/j.cjca.2018.04.002_bib13 article-title: Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1604304 contributor: fullname: Ference – volume: 32 start-page: 1263 year: 2016 ident: 10.1016/j.cjca.2018.04.002_bib1 article-title: 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult publication-title: Can J Cardiol doi: 10.1016/j.cjca.2016.07.510 contributor: fullname: Anderson – volume: 64 start-page: 401 year: 2011 ident: 10.1016/j.cjca.2018.04.002_bib9 article-title: GRADE guidelines: 3. Rating the quality of evidence publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2010.07.015 contributor: fullname: Balshem – volume: 376 start-page: 1713 year: 2017 ident: 10.1016/j.cjca.2018.04.002_bib5 article-title: Evolocumab and clinical outcomes in patients with cardiovascular disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1615664 contributor: fullname: Sabatine – volume: 70 start-page: 2677 year: 2017 ident: 10.1016/j.cjca.2018.04.002_bib12 article-title: PCSK9 inhibitors: economics and policy publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2017.10.001 contributor: fullname: Hlatky – volume: 33 start-page: 405 year: 2017 ident: 10.1016/j.cjca.2018.04.002_bib3 article-title: Optimal low-density lipoprotein cholesterol for cardiovascular prevention: how low should we go? publication-title: Can J Cardiol doi: 10.1016/j.cjca.2016.12.007 contributor: fullname: Anderson – start-page: CD011748 issue: 4 year: 2017 ident: 10.1016/j.cjca.2018.04.002_bib10 article-title: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease publication-title: Cochrane Database Syst Rev contributor: fullname: Schmidt – volume: 6 start-page: e1000100 year: 2009 ident: 10.1016/j.cjca.2018.04.002_bib7 article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration publication-title: PLoS Med doi: 10.1371/journal.pmed.1000100 contributor: fullname: Liberati – ident: 10.1016/j.cjca.2018.04.002_bib6 doi: 10.1056/NEJMoa1801174 – volume: 6 start-page: e006910 year: 2017 ident: 10.1016/j.cjca.2018.04.002_bib11 article-title: Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials publication-title: J Am Heart Assoc doi: 10.1161/JAHA.117.006910 contributor: fullname: Karatasakis – volume: 132 start-page: 1648 year: 2015 ident: 10.1016/j.cjca.2018.04.002_bib4 article-title: Proprotein convertase subtilisin/kexin type 9 inhibition a new therapeutic mechanism for reducing cardiovascular disease risk publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.115.016080 contributor: fullname: Bergeron – volume: 33 start-page: 343 year: 2017 ident: 10.1016/j.cjca.2018.04.002_bib2 article-title: An evidence-based guide to cholesterol-lowering guidelines publication-title: Can J Cardiol doi: 10.1016/j.cjca.2016.10.019 contributor: fullname: Waters |
SSID | ssj0041776 |
Score | 2.424981 |
SecondaryResourceType | review_article |
Snippet | Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents, but more precise estimates of their effects on major... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1600 |
SubjectTerms | Antibodies, Monoclonal - therapeutic use Anticholesteremic Agents - therapeutic use Cardiovascular Diseases - mortality Coronary Artery Disease - drug therapy Humans Mortality Primary Prevention Proprotein Convertase 9 - antagonists & inhibitors Randomized Controlled Trials as Topic Secondary Prevention |
Title | Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial |
URI | https://dx.doi.org/10.1016/j.cjca.2018.04.002 https://www.ncbi.nlm.nih.gov/pubmed/30527147 https://search.proquest.com/docview/2155149168 |
Volume | 34 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pa9swFH60KYxdxn4v-1E02G1osWxZVnYrXkq6kmbgBNKTkGSJpQynbM6hl7E_fU-2XChsOwyfbCQs9KTvfdJ7-gTwTkth6ixj1LmkoIh-BTVIE6jRAvkBy6U0YR9ycSHma_55k28OoBzOwoS0yoj9PaZ3aB2_TGJvTq6320kVxNfw2bAgYYXz9hCO0B1xPoKjk7Pz-cUAyJwV3R1zoTwNFeLZmT7Ny17ZID_EZKd4GndX_uCf_sY_Oz90-hAeRAJJTvo2PoID1zyGe4sYIn8Cv8o7GaZkFjQitL0huqlJpb1rb8jOky9ldT4lZ83XrdmGC3c-kupW05n0AYOuxsK1muqoXILl7bd98HYEeSNZfrqsqtklWa5X5XIxq8gqjOansD6drco5jdcsUJvloqV1ioAoapOJRJtESFy0ptoXJgQEvWPWeqR4iXWeixrZg5beT4UpmOHTxOc2zZ7BqNk17gWQTIosE9ziKmTKjdSGF8gXncuZqw0zyRjeD52rrns1DTWkmV2pYAoVTKESrtAUY8iH_ld3xoRCuP9nvbeDsRROlhAB0Y3b7X-otCOIyIjlGJ73VrxtBwJfWjBevPzPv76C--GtT3V5DaP2-969QcLSmmM4_PCTHcdh-RsPW-cu |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLbGkIAL4jeFAUbihkLjxHFcblPo1LFlRUordSfLdmzRCaUTpIdd0P70vZc4lSYBB5RbYivWe_bzZ7_Pnwn5oKUwdZqyyLk4jyD65ZEBmBAZLQAfsExKg_uQ5ZmYLfnXVbbaI8VwFgZplSH29zG9i9bhzThYc3y5Xo8rFF-DZ8VQwgrG7R1yF9EA8ro-_d7xPDjLuxvmsHSExcPJmZ7kZS8sig8x2emdhr2VP8xOf0Of3Sx09Ig8DPCRHvYtfEz2XPOE3CtDgvwpuS5u8UvpFBUitL2iuqlppb1rr-jG029FdTKhx833tVnjdTufabVTdKZ9uqCrUbpWRzrolkB5-2OLcx0F1EjnX86ranpO58tFMS-nFV1gX35GlkfTRTGLwiULkU0z0UZ1AuFQ1CYVsTaxkLBkTbTPDaYDvWPWegB4sXWeixqwg5beT4TJmeGT2Gc2SZ-T_WbTuJeEplKkqeAW1iATbqQ2PAe06FzGXG2YiUfk42BcddlraaiBZHah0BUKXaFirsAVI5IN9le3eoSCYP_Peu8HZykYKpj_0I3bbH-ppIOHgIfliLzovbhrB4S9JGc8f_Wff31H7s8W5ak6PT47eU0e4Jee9HJA9tufW_cGoEtr3nZd8wYYGugD |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiovascular+Efficacy+and+Safety+of+PCSK9+Inhibitors%3A+Systematic+Review+and+Meta-analysis+Including+the+ODYSSEY+OUTCOMES+Trial&rft.jtitle=Canadian+journal+of+cardiology&rft.au=Turgeon%2C+Ricky+D&rft.au=Tsuyuki%2C+Ross+T&rft.au=Gyenes%2C+Gabor+T&rft.au=Pearson%2C+Glen+J&rft.date=2018-12-01&rft.eissn=1916-7075&rft.volume=34&rft.issue=12&rft.spage=1600&rft_id=info:doi/10.1016%2Fj.cjca.2018.04.002&rft_id=info%3Apmid%2F30527147&rft.externalDocID=30527147 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0828-282X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0828-282X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0828-282X&client=summon |